Scholarlink

Background <p>Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis and limited treatment options. Chemokine receptor type 4 (CXCR4) plays a key role in GBM invasion and therapy resistance, making it an attractive target for molecular imaging and theranostics. We developed [<sup>68</sup>Ga]Ga-TD-01, a next-generation positron emission tomography (PET) radiotracer for CXCR4 imaging, and evaluated its pharmacokinetics, dosimetry, and translational potential.</p> Results <p>In mice bearing orthotopic GL261 GBM, dynamic PET/MRI, receptor blocking studies, and kinetic modeling demonstrated a specific binding component and high tumor-to-background contrast. [<sup>68</sup>Ga]Ga-TD-01 showed high tumor uptake (5.4 ± 4.3%ID/g at 9&#xa0;min), low uptake in normal brain (2.2 ± 1.7%ID/g), and a tumor-to-background ratio of 2.9 ± 0.2 at 60&#xa0;min, which was significantly reduced by CXCR4 blockade. PET pharmacokinetic modeling confirmed increased tumor retention (Vt of 0.5 ± 0.07&#xa0;ml/cm<sup>3</sup> for tumor; Vt of 0.2 ± 0.05&#xa0;ml/cm<sup>3</sup> for brain). The radiotracer exhibited high in vivo stability, rapid renal clearance, and favorable biodistribution. CXCR4 expression was confirmed in both murine and human GBM tissues by RNAscope. Human dosimetry extrapolation estimated an effective dose of 4.6&#xa0;mSv for a standard PET scan, comparable to approved tracers.</p> Conclusions <p>When compared with reported data for [<sup>68</sup>Ga]Ga-Pentixafor, [<sup>68</sup>Ga]Ga-TD-01 showed tumor uptake within the reported range and low background accumulation; however, no direct head-to-head comparison was performed. These results support [<sup>68</sup>Ga]Ga-TD-01 as a promising CXCR4-targeted imaging agent and a candidate for further theranostic development.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

CXCR4-targeted PET imaging of glioblastoma using [68Ga]Ga-TD-01: from pharmacokinetics and dosimetry to theranostic potential

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月21日

查看全文
  • Piyapan Suwattananuruk,
  • Stine Figenschau,
  • Angel Moldes-Anaya,
  • Efat Muhammad Arshad,
  • Rodrigo Berzaghi,
  • Lars Kjelsberg Pedersen,
  • Rune Sundset,
  • Pornchai Rojsitthisak,
  • Opa Vajragupta,
  • Mathias Kranz

摘要

Background

Glioblastoma multiforme (GBM) is an aggressive brain tumor with poor prognosis and limited treatment options. Chemokine receptor type 4 (CXCR4) plays a key role in GBM invasion and therapy resistance, making it an attractive target for molecular imaging and theranostics. We developed [68Ga]Ga-TD-01, a next-generation positron emission tomography (PET) radiotracer for CXCR4 imaging, and evaluated its pharmacokinetics, dosimetry, and translational potential.

Results

In mice bearing orthotopic GL261 GBM, dynamic PET/MRI, receptor blocking studies, and kinetic modeling demonstrated a specific binding component and high tumor-to-background contrast. [68Ga]Ga-TD-01 showed high tumor uptake (5.4 ± 4.3%ID/g at 9 min), low uptake in normal brain (2.2 ± 1.7%ID/g), and a tumor-to-background ratio of 2.9 ± 0.2 at 60 min, which was significantly reduced by CXCR4 blockade. PET pharmacokinetic modeling confirmed increased tumor retention (Vt of 0.5 ± 0.07 ml/cm3 for tumor; Vt of 0.2 ± 0.05 ml/cm3 for brain). The radiotracer exhibited high in vivo stability, rapid renal clearance, and favorable biodistribution. CXCR4 expression was confirmed in both murine and human GBM tissues by RNAscope. Human dosimetry extrapolation estimated an effective dose of 4.6 mSv for a standard PET scan, comparable to approved tracers.

Conclusions

When compared with reported data for [68Ga]Ga-Pentixafor, [68Ga]Ga-TD-01 showed tumor uptake within the reported range and low background accumulation; however, no direct head-to-head comparison was performed. These results support [68Ga]Ga-TD-01 as a promising CXCR4-targeted imaging agent and a candidate for further theranostic development.